Published date: 20 February 2017
Closed opportunity - This means that the contract is currently closed. The buying department may be considering suppliers that have already applied, or no suitable offers were made.
Contract summary
Industry
Research and development services and related consultancy services - 73000000
Location of contract
North East
Value of contract
£640,000 to £800,000
Procurement reference
NCL001-DN240581-52736668
Published date
20 February 2017
Closing date
22 March 2017
Contract start date
17 April 2017
Contract end date
30 November 2020
Contract type
Service contract
Procedure type
Open procedure
Any interested supplier may submit a tender in response to an opportunity notice.
Contract is suitable for SMEs?
No
Contract is suitable for VCSEs?
No
Description
This is an EU Open Tender. The scope of this contract relates specifically to the Phase 2b Randomized, Double-blind, Parallel Placebo- and Active-controlled Study to Assess the Efficacy and Safety of Vamorolone in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) and the extension study that will follow this. A registered Clinical Trial Unit (CTU) or Contracted Research Organisation (CRO) is required to set up and manage the clinical trial at sites in [UK/Australia/Israel/Sweden]. The CTU / CRO will be carrying out delegated duties on behalf of the sponsor, ReveraGen, but will be receiving payments for these duties from the Vision-DMD Horizon 2020 grant, coordinated by Newcastle University. This contract consists of 4 separate geographical Lots:
Lot 1: UK
Lot 2: Australia
Lot 3: Israel
Lot 4: Sweden
About the buyer
Contact name
Gillian Mournian
Address
Kings Gate
Newcastle upon Tyne
NE1 7RU
England
Telephone
0191 2086073
Share this notice
Closing: 22 March 2017
All content is available under the
